Welcome to our dedicated page for Pds Biotechnology Corporation SEC filings (Ticker: PDSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech is tough: every 10-K details R&D burn, every 8-K flags trial milestones, and each Form 4 signals how insiders view the data. PDS Biotechnology’s Versamune immunotherapy pipeline makes those documents even denser, with pages of scientific terminology and partnership terms. Investors ask, “Where can I find the PDS Biotechnology quarterly earnings report 10-Q filing?” or “How do the latest PDS Biotechnology insider trading Form 4 transactions affect valuation?” We surface the answers immediately.
Stock Titan’s AI reads each filing the moment it hits EDGAR, then delivers line-by-line explanations in plain English. You’ll see PDS Biotechnology Form 4 insider transactions real-time, concise tables summarizing R&D expense trends, and straightforward callouts for 8-K material events. Our summaries cut through legal language so PDS Biotechnology SEC filings explained simply becomes reality. Want the PDS Biotechnology annual report 10-K simplified? One click shows Versamune trial timelines, patent cliffs, and liquidity analysis. For deeper context, a side panel is dedicated to understanding PDS Biotechnology SEC documents with AI and source links.
Beyond summaries, we connect filing types to the questions professionals actually ask. The proxy statement executive compensation section links CEO pay to clinical milestones; the PDS Biotechnology earnings report filing analysis tracks quarter-over-quarter cash use; insider data surfaces PDS Biotechnology executive stock transactions Form 4 ahead of pivotal readouts. Use our platform to monitor PDS Biotechnology proxy statement executive compensation, compare segment spending across trials, and download spreadsheets for deeper modelling. Whether you need PDS Biotechnology 8-K material events explained or a quick refresher on clinical timelines, everything is in one place, updated instantly.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,283,288 shares of PDS Biotechnology Corp (CUSIP 70465T107), representing 4.99% of the outstanding common stock. The filing states that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital and Mr. Boyd exercise shared voting and dispositive power over the reported shares while having no sole voting or dispositive power.
The Reporting Persons certify the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The Schedule 13G/A is executed jointly by Armistice Capital and Steven Boyd and dated August 14, 2025.
PDS Biotechnology reported $31.9 million in cash and cash equivalents and a consolidated net loss of $9.4 million for the quarter and $17.9 million for the six months ended June 30, 2025. Total assets were $40.5 million and total liabilities were $24.5 million, leaving stockholders' equity of $16.0 million and an accumulated deficit of $200.0 million. Shares outstanding increased to 46,633,362. The company used $18.1 million of cash in operating activities during the first half of 2025 and reduced cash from $41.7 million at year-end 2024 to $31.9 million at June 30, 2025.
PDSB completed financings in early 2025, including a February offering that generated net proceeds of about $10.05 million and a securities purchase agreement that raised $20.0 million (including $22.22 million principal debentures) used largely to retire prior debt. The debentures carry a high effective annual interest rate (~24.1%) and include cash-maintenance and customary restrictive covenants. The company disclosed substantial doubt about its ability to continue as a going concern for at least 12 months. Clinically, PDSB advanced VERSATILE-003 into Phase 3 and reported multiple encouraging trial updates and a JAMA Oncology publication showing strong survival and response results in certain cohorts.
FAQ
What is the current stock price of Pds Biotechnology Corporation (PDSB)?
What is the market cap of Pds Biotechnology Corporation (PDSB)?
